Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453952 | 1.00 | ADORA2A (0.57) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL29421357 | 1.00 | ADORA2A (0.57) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL453953 | 1.00 | ADORA2A (0.57) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL28630248 | 0.95 | ADORA2A (0.57) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL16555098 | 0.94 | TARS1 (0.54) | ADORA2AADORA2B | |
| SCHEMBL29047902 | 0.93 | ADORA2A (0.60) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL29047905 | 0.93 | ADORA2A (0.60) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL28964452 | 0.92 | ADORA2A (0.56) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL28964455 | 0.92 | ADORA2A (0.56) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL2033392 | 0.91 | TARS1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3112 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250382669-A1 | METHOD FOR ANALYZING MODIFIED NUCLEOSIDE | SHIMADZU CORPORATION (JP) | 2025-12-18 | — | — | US | claimed |
| US-20250345406-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | SHATTUCK LABS INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-10-23 | — | — | US | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025151711-A1 | NUCLEIC ACID VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025122721-A1 | CHIMERIC PROTEINS AND USES THEREOF | SHATTUCK LABS, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| WO-2013151672-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013039861-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2012158736-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | modeRNA Therapeutics (US) | 2012-11-22 | — | — | WO | claimed |
| WO-2012135805-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | WO | claimed |
| US-20120251618-A1 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | US | claimed |
| WO-2012130941-A2 | PERFLUORINATED COMPOUNDS FOR THE NON-VIRAL TRANSFER OF NUCLEIC ACIDS | SCHAEFER KONSTANZE (DE) | 2012-10-04 | — | — | WO | claimed |
| EP-2201118-B1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2012-04-18 | — | — | EP | claimed |
| US-20100291032-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2010-11-18 | — | — | US | claimed |
| EP-2201118-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | Trana Discovery (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009036299-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2009-03-19 | — | — | WO | claimed |